Evidence map›Paper›PMID 42812841›Full record

ArticleMedComm2026

Optimal, Interpretable, and Personalized Immune Checkpoint Inhibitor Duration in Non-Small Cell Lung Cancer: A Multicenter Real-World Study.

Siqi Wang, Jianhua Liu, Qiang Nie, Ruichuan Shi, Nan Xu, Qianqian He, Guanchao Ye, Jingyi Liu, Qiuyang Hou, Kexue Deng and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Siqi Wang *School of Health Management China Medical University Shenyang Liaoning China.
Jianhua Liu *Department of Oncology Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences) Southern Medical University Guangzhou China.
Qiang Nie *Department of Pulmonary Surgery Guangdong Lung Cancer Institute Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences) Southern Medical University Guangzhou China.
Ruichuan Shi *Department of Medical Oncology The First Hospital of China Medical University Shenyang Liaoning Province China.
Nan XuSchool of Health Management China Medical University Shenyang Liaoning China.
Qianqian HeSchool of Health Management China Medical University Shenyang Liaoning China.
Guanchao YeDepartment of Thoracic Surgery The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan China.
Jingyi LiuThe First Hospital of China Medical University Shenyang Liaoning China.
Qiuyang HouDivision of Life Sciences and Medicine Department of Radiology The First Affiliated Hospital of University of Science and Technology of China (USTC) Hefei Anhui China.
Kexue DengDivision of Life Sciences and Medicine Department of Radiology The First Affiliated Hospital of University of Science and Technology of China (USTC) Hefei Anhui China.
Lu WangShengjing Hospital of China Medical University Shenyang Liaoning China.
Taixue AnDepartment of Laboratory Medicine Nanfang Hospital Southern Medical University Guangzhou China.
Anyi AnJinzhou Medical University Jinzhou Liaoning Province China.
Xiujuan QuDepartment of Medical Oncology The First Hospital of China Medical University Shenyang Liaoning Province China.ORCID https://orcid.org/0009-0005-9366-2314
Jiangdian SongSchool of Health Management China Medical University Shenyang Liaoning China.ORCID https://orcid.org/0000-0002-3355-9930

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The optimal treatment duration of immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC) remains undefined. We conducted a multicenter retrospective cohort study of 1054 patients with NSCLC treated with ICIs across six hospitals in China and one in the United States. Using a training cohort of 372 patients, we constructed a counterfactual random forest reward-estimation matrix incorporating age, tumor diameter, and derived neutrophil-to-lymphocyte ratio, and an Optimal Policy Survival Tree (OPST) was developed to characterize phenotype-specific associations between baseline clinical features, treatment duration patterns (short-, intermediate-, and long-course), and survival outcomes. Two external cohorts (

Indexed as

decision‐makingimmunotherapynon‐small cell lung cancerprognosistreatment duration

Identifiers

PMID42812841
PMCPMC13620853

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.